On December 2, 2024, Howard Welgus, a Director at Arcutis Biotherapeutics Inc (ARQT, Financial), sold 10,000 shares of the company, as reported in a SEC Filing. Following this transaction, the insider now owns 161,944 shares of the company.
Arcutis Biotherapeutics Inc (ARQT) is a biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases. The company's mission is to address significant unmet needs in dermatology by providing innovative therapies.
The insider's recent transaction is part of a broader trend observed over the past year. Howard Welgus has sold a total of 70,000 shares and has not purchased any shares during this period. This activity is consistent with the overall insider transaction history for Arcutis Biotherapeutics Inc, which shows 4 insider buys and 32 insider sells over the past year.
On the day of the transaction, shares of Arcutis Biotherapeutics Inc were trading at $12.51 each, resulting in a market cap of $1.436 billion. Investors may consider this information in the context of the company's valuation metrics, such as the GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow.
This insider sell activity may be of interest to investors who are monitoring the trading patterns of company insiders as part of their investment strategy.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
